Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West Japan Thoracic Oncology Group

Criteria

Inclusion Criteria:

1. completely resected non small cell lung cancer

2. no prior anti cancer treatment for thoracic malignancy exept for this operation

3. pathological stage IB, II, and stage IIIA with only one station of n2 disease

4. PS 0-1

5. age 20-75

6. adequate organ function for chemotherapy

7. written informed consent

Exclusion Criteria:

1. small cell lung cancer or low grade malignancy of lung cancer

2. incomplete resection

3. apparent interstitial pneumonitis at chest rentogenogram

4. inadequate condition for chemotherapy